Advanced search
Start date
Betweenand


Nanocrystal's Formulation of Biological Response Modifier P-MAPA on Bladder Cancer Compared to Bacillus Calmette-Guerin Immunomodulator

Full text
Author(s):
Favaro, Wagner Jose ; Silva Lima, Ana Claudia ; Dias, Queila Cristina ; Garcia, Patrick Vianna ; Duran, Nelson
Total Authors: 5
Document type: Journal article
Source: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY; v. 37, n. 2, p. 11-pg., 2022-02-28.
Abstract

OBJECTIVE P-MAPA (200-400 mu m) is known that exhibited significant in vivo antitumor activity, unfortunately with low capacity of suspension. Our aim is to study the effects of nanocrystals (400-600 nm) produced by nanonization compared to bacillus Calmette-Guerin (BCG) vaccine on bladder cancer at a non-muscle invasive stage (NMIBC). METHODS To induce NMIBC, 20 female Fischer 344 rats received intravesically 1.5 mg/kg dose of N-methyl-N-nitrosourea (MNU), and control animals were injected with PBS solution. After cancer induction, MNU (cancer) group received identical treatment that control group; a group received 106 CFU dose of BCG for 6 weeks; P- MAPA-Nano + Pluronic group was injected with intravesically 0.8 mg/kg dose of P-MAPA for 6 weeks. A histopathological analysis of bladder after 16 weeks was carried out. Following the same procedure, the P-MAPA-Nano-Chitosan was studied. RESULTS In P-MAPA-Nano+Pluronic crystals, a better antitumor activity than BCG treatment was found and correlated with the apoptosis raised. However, unfortunately in the case of chitosan as stabilizer, the effect was negligible. One reasonable explanation to this low effect was probably through a drastic pH change (basic) in the urinary bladder in cancer case. CONCLUSION The results demonstrated that this new nanoformulation of P MAPA in the presence of Pluronic F68 could be a potential candidate for treatment of in vivo bladder cancer. (AU)

FAPESP's process: 12/16880-7 - Comparative Study of the Effects of Immunomodulator P-MAPA Encapsulated with Mucoadhesive Polymeric Nanoparticles versus BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer Progression
Grantee:Ana Claudia da Silva Lima
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 12/11002-1 - Molecular and histopathological evaluation of nanostructured formulations of immunomodulator P-MAPA effects versus BCG immunotherapy in non-muscle invasive bladder cancer (NMIBC) progression
Grantee:Wagner José Fávaro
Support Opportunities: Regular Research Grants